Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 197

1.

Chimeric antigen receptor-modified T cells: CD19 and the road beyond.

Salter AI, Pont MJ, Riddell SR.

Blood. 2018 Jun 14;131(24):2621-2629. doi: 10.1182/blood-2018-01-785840. Epub 2018 May 4. Review.

PMID:
29728402
2.

Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman Primates.

Taraseviciute A, Tkachev V, Ponce R, Turtle CJ, Snyder JM, Liggitt HD, Myerson D, Gonzalez-Cuyar L, Baldessari A, English C, Yu A, Zheng H, Furlan SN, Hunt DJ, Hoglund V, Finney O, Brakke H, Blazar BR, Berger C, Riddell SR, Gardner R, Kean LS, Jensen MC.

Cancer Discov. 2018 Jun;8(6):750-763. doi: 10.1158/2159-8290.CD-17-1368. Epub 2018 Mar 21.

PMID:
29563103
3.

Tumor-infiltrating BRAFV600E-specific CD4+ T cells correlated with complete clinical response in melanoma.

Veatch JR, Lee SM, Fitzgibbon M, Chow IT, Jesernig B, Schmitt T, Kong YY, Kargl J, Houghton AM, Thompson JA, McIntosh M, Kwok WW, Riddell SR.

J Clin Invest. 2018 Apr 2;128(4):1563-1568. doi: 10.1172/JCI98689. Epub 2018 Mar 12.

4.

Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy.

Srivastava S, Riddell SR.

J Immunol. 2018 Jan 15;200(2):459-468. doi: 10.4049/jimmunol.1701155. Review.

PMID:
29311388
5.

Preclinical Optimization of a CD20-specific Chimeric Antigen Receptor Vector and Culture Conditions.

Lee SY, Olsen P, Lee DH, Kenoyer AL, Budde LE, O'Steen S, Green DJ, Heimfeld S, Jensen MC, Riddell SR, Press OW, Till BG.

J Immunother. 2018 Jan;41(1):19-31. doi: 10.1097/CJI.0000000000000199.

PMID:
29176334
6.

Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy.

Hill JA, Li D, Hay KA, Green ML, Cherian S, Chen X, Riddell SR, Maloney DG, Boeckh M, Turtle CJ.

Blood. 2018 Jan 4;131(1):121-130. doi: 10.1182/blood-2017-07-793760. Epub 2017 Oct 16.

PMID:
29038338
7.

Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells.

Gust J, Hay KA, Hanafi LA, Li D, Myerson D, Gonzalez-Cuyar LF, Yeung C, Liles WC, Wurfel M, Lopez JA, Chen J, Chung D, Harju-Baker S, Özpolat T, Fink KR, Riddell SR, Maloney DG, Turtle CJ.

Cancer Discov. 2017 Dec;7(12):1404-1419. doi: 10.1158/2159-8290.CD-17-0698. Epub 2017 Oct 12.

PMID:
29025771
8.

Graft-Derived Reconstitution of Mucosal-Associated Invariant T Cells after Allogeneic Hematopoietic Cell Transplantation.

Bhattacharyya A, Hanafi LA, Sheih A, Golob JL, Srinivasan S, Boeckh MJ, Pergam SA, Mahmood S, Baker KK, Gooley TA, Milano F, Fredricks DN, Riddell SR, Turtle CJ.

Biol Blood Marrow Transplant. 2018 Feb;24(2):242-251. doi: 10.1016/j.bbmt.2017.10.003. Epub 2017 Oct 9.

PMID:
29024803
9.

Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.

Hay KA, Hanafi LA, Li D, Gust J, Liles WC, Wurfel MM, López JA, Chen J, Chung D, Harju-Baker S, Cherian S, Chen X, Riddell SR, Maloney DG, Turtle CJ.

Blood. 2017 Nov 23;130(21):2295-2306. doi: 10.1182/blood-2017-06-793141. Epub 2017 Sep 18.

PMID:
28924019
10.

Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.

Turtle CJ, Hay KA, Hanafi LA, Li D, Cherian S, Chen X, Wood B, Lozanski A, Byrd JC, Heimfeld S, Riddell SR, Maloney DG.

J Clin Oncol. 2017 Sep 10;35(26):3010-3020. doi: 10.1200/JCO.2017.72.8519. Epub 2017 Jul 17.

PMID:
28715249
11.

T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.

Pollack SM, He Q, Yearley JH, Emerson R, Vignali M, Zhang Y, Redman MW, Baker KK, Cooper S, Donahue B, Loggers ET, Cranmer LD, Spraker MB, Seo YD, Pillarisetty VG, Ricciotti RW, Hoch BL, McClanahan TK, Murphy E, Blumenschein WM, Townson SM, Benzeno S, Riddell SR, Jones RL.

Cancer. 2017 Sep 1;123(17):3291-3304. doi: 10.1002/cncr.30726. Epub 2017 May 2.

12.

Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults.

Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K, Bleakley M, Brown C, Mgebroff S, Kelly-Spratt KS, Hoglund V, Lindgren C, Oron AP, Li D, Riddell SR, Park JR, Jensen MC.

Blood. 2017 Jun 22;129(25):3322-3331. doi: 10.1182/blood-2017-02-769208. Epub 2017 Apr 13.

13.

Fully human CD19-specific chimeric antigen receptors for T-cell therapy.

Sommermeyer D, Hill T, Shamah SM, Salter AI, Chen Y, Mohler KM, Riddell SR.

Leukemia. 2017 Oct;31(10):2191-2199. doi: 10.1038/leu.2017.57. Epub 2017 Feb 16.

14.

Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues.

Balakrishnan A, Goodpaster T, Randolph-Habecker J, Hoffstrom BG, Jalikis FG, Koch LK, Berger C, Kosasih PL, Rajan A, Sommermeyer D, Porter PL, Riddell SR.

Clin Cancer Res. 2017 Jun 15;23(12):3061-3071. doi: 10.1158/1078-0432.CCR-16-2083. Epub 2016 Nov 16.

15.

Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia.

Paszkiewicz PJ, Fräßle SP, Srivastava S, Sommermeyer D, Hudecek M, Drexler I, Sadelain M, Liu L, Jensen MC, Riddell SR, Busch DH.

J Clin Invest. 2016 Nov 1;126(11):4262-4272. doi: 10.1172/JCI84813. Epub 2016 Oct 17.

16.

Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.

Turtle CJ, Hanafi LA, Berger C, Hudecek M, Pender B, Robinson E, Hawkins R, Chaney C, Cherian S, Chen X, Soma L, Wood B, Li D, Heimfeld S, Riddell SR, Maloney DG.

Sci Transl Med. 2016 Sep 7;8(355):355ra116. doi: 10.1126/scitranslmed.aaf8621.

17.

Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab.

Rufener GA, Press OW, Olsen P, Lee SY, Jensen MC, Gopal AK, Pender B, Budde LE, Rossow JK, Green DJ, Maloney DG, Riddell SR, Till BG.

Cancer Immunol Res. 2016 Jun;4(6):509-19. doi: 10.1158/2326-6066.CIR-15-0276. Epub 2016 Apr 21.

18.

CD19-Targeted chimeric antigen receptor-modified T-cell immunotherapy for B-cell malignancies.

Turtle CJ, Riddell SR, Maloney DG.

Clin Pharmacol Ther. 2016 Sep;100(3):252-8. doi: 10.1002/cpt.392. Epub 2016 Jun 17.

PMID:
27170467
19.

Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL.

Wang X, Popplewell LL, Wagner JR, Naranjo A, Blanchard MS, Mott MR, Norris AP, Wong CW, Urak RZ, Chang WC, Khaled SK, Siddiqi T, Budde LE, Xu J, Chang B, Gidwaney N, Thomas SH, Cooper LJ, Riddell SR, Brown CE, Jensen MC, Forman SJ.

Blood. 2016 Jun 16;127(24):2980-90. doi: 10.1182/blood-2015-12-686725. Epub 2016 Apr 26.

20.

CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.

Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, Sommermeyer D, Melville K, Pender B, Budiarto TM, Robinson E, Steevens NN, Chaney C, Soma L, Chen X, Yeung C, Wood B, Li D, Cao J, Heimfeld S, Jensen MC, Riddell SR, Maloney DG.

J Clin Invest. 2016 Jun 1;126(6):2123-38. doi: 10.1172/JCI85309. Epub 2016 Apr 25.

21.

Role of memory T cell subsets for adoptive immunotherapy.

Busch DH, Fräßle SP, Sommermeyer D, Buchholz VR, Riddell SR.

Semin Immunol. 2016 Feb;28(1):28-34. doi: 10.1016/j.smim.2016.02.001. Epub 2016 Mar 11. Review.

22.

Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy.

Gardner R, Wu D, Cherian S, Fang M, Hanafi LA, Finney O, Smithers H, Jensen MC, Riddell SR, Maloney DG, Turtle CJ.

Blood. 2016 May 19;127(20):2406-10. doi: 10.1182/blood-2015-08-665547. Epub 2016 Feb 23.

23.

Inclusion of Strep-tag II in design of antigen receptors for T-cell immunotherapy.

Liu L, Sommermeyer D, Cabanov A, Kosasih P, Hill T, Riddell SR.

Nat Biotechnol. 2016 Apr;34(4):430-4. doi: 10.1038/nbt.3461. Epub 2016 Feb 22.

24.

TALEN-mediated genetic inactivation of the glucocorticoid receptor in cytomegalovirus-specific T cells.

Menger L, Gouble A, Marzolini MA, Pachnio A, Bergerhoff K, Henry JY, Smith J, Pule M, Moss P, Riddell SR, Quezada SA, Peggs KS.

Blood. 2015 Dec 24;126(26):2781-9. doi: 10.1182/blood-2015-08-664755. Epub 2015 Oct 27.

25.

A BiTE from cancer's intracellular menu.

Salter AI, Riddell SR.

Nat Biotechnol. 2015 Oct;33(10):1040-1. doi: 10.1038/nbt.3370. No abstract available.

PMID:
26448086
26.

Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo.

Sommermeyer D, Hudecek M, Kosasih PL, Gogishvili T, Maloney DG, Turtle CJ, Riddell SR.

Leukemia. 2016 Feb;30(2):492-500. doi: 10.1038/leu.2015.247. Epub 2015 Sep 15.

27.

Engineering CAR-T cells: Design concepts.

Srivastava S, Riddell SR.

Trends Immunol. 2015 Aug;36(8):494-502. doi: 10.1016/j.it.2015.06.004. Epub 2015 Jul 11. Review.

28.

Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts.

Bleakley M, Heimfeld S, Loeb KR, Jones LA, Chaney C, Seropian S, Gooley TA, Sommermeyer F, Riddell SR, Shlomchik WD.

J Clin Invest. 2015 Jul 1;125(7):2677-89. doi: 10.1172/JCI81229. Epub 2015 Jun 8.

29.

Adoptive cellular therapy: a race to the finish line.

June CH, Riddell SR, Schumacher TN.

Sci Transl Med. 2015 Mar 25;7(280):280ps7. doi: 10.1126/scitranslmed.aaa3643. Review.

PMID:
25810311
30.

Designing chimeric antigen receptors to effectively and safely target tumors.

Jensen MC, Riddell SR.

Curr Opin Immunol. 2015 Apr;33:9-15. doi: 10.1016/j.coi.2015.01.002. Epub 2015 Jan 23. Review.

31.

Cytotoxic T-cell cytokines put cancer under arrest.

Riddell SR.

Cancer Immunol Res. 2015 Jan;3(1):23-5. doi: 10.1158/2326-6066.CIR-14-0218. Epub 2014 Dec 17. No abstract available.

32.

Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells.

Berger C, Sommermeyer D, Hudecek M, Berger M, Balakrishnan A, Paszkiewicz PJ, Kosasih PL, Rader C, Riddell SR.

Cancer Immunol Res. 2015 Feb;3(2):206-16. doi: 10.1158/2326-6066.CIR-14-0163. Epub 2014 Oct 29.

33.

Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells.

Pollack SM, Jones RL, Farrar EA, Lai IP, Lee SM, Cao J, Pillarisetty VG, Hoch BL, Gullett A, Bleakley M, Conrad EU 3rd, Eary JF, Shibuya KC, Warren EH, Carstens JN, Heimfeld S, Riddell SR, Yee C.

J Immunother Cancer. 2014 Oct 14;2(1):36. doi: 10.1186/s40425-014-0036-y. eCollection 2014.

34.

The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity.

Hudecek M, Sommermeyer D, Kosasih PL, Silva-Benedict A, Liu L, Rader C, Jensen MC, Riddell SR.

Cancer Immunol Res. 2015 Feb;3(2):125-35. doi: 10.1158/2326-6066.CIR-14-0127. Epub 2014 Sep 11.

35.

Serial transfer of single-cell-derived immunocompetence reveals stemness of CD8(+) central memory T cells.

Graef P, Buchholz VR, Stemberger C, Flossdorf M, Henkel L, Schiemann M, Drexler I, Höfer T, Riddell SR, Busch DH.

Immunity. 2014 Jul 17;41(1):116-26. doi: 10.1016/j.immuni.2014.05.018.

36.

Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment.

Shibuya KC, Goel VK, Xiong W, Sham JG, Pollack SM, Leahy AM, Whiting SH, Yeh MM, Yee C, Riddell SR, Pillarisetty VG.

PLoS One. 2014 May 2;9(5):e96565. doi: 10.1371/journal.pone.0096565. eCollection 2014.

37.

Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition.

Riddell SR, Sommermeyer D, Berger C, Liu LS, Balakrishnan A, Salter A, Hudecek M, Maloney DG, Turtle CJ.

Cancer J. 2014 Mar-Apr;20(2):141-4. doi: 10.1097/PPO.0000000000000036. Review.

38.

Engineering human peripheral blood stem cell grafts that are depleted of naïve T cells and retain functional pathogen-specific memory T cells.

Bleakley M, Heimfeld S, Jones LA, Turtle C, Krause D, Riddell SR, Shlomchik W.

Biol Blood Marrow Transplant. 2014 May;20(5):705-16. doi: 10.1016/j.bbmt.2014.01.032. Epub 2014 Feb 11.

39.

Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma.

Budde LE, Berger C, Lin Y, Wang J, Lin X, Frayo SE, Brouns SA, Spencer DM, Till BG, Jensen MC, Riddell SR, Press OW.

PLoS One. 2013 Dec 17;8(12):e82742. doi: 10.1371/journal.pone.0082742. eCollection 2013.

40.

Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells.

Jensen MC, Riddell SR.

Immunol Rev. 2014 Jan;257(1):127-44. doi: 10.1111/imr.12139. Review. Erratum in: Immunol Rev. 2014 Mar;258(1):259.

41.

HLA-F and MHC-I open conformers cooperate in a MHC-I antigen cross-presentation pathway.

Goodridge JP, Lee N, Burian A, Pyo CW, Tykodi SS, Warren EH, Yee C, Riddell SR, Geraghty DE.

J Immunol. 2013 Aug 15;191(4):1567-77. doi: 10.4049/jimmunol.1300080. Epub 2013 Jul 12.

42.

TCR-ligand koff rate correlates with the protective capacity of antigen-specific CD8+ T cells for adoptive transfer.

Nauerth M, Weißbrich B, Knall R, Franz T, Dössinger G, Bet J, Paszkiewicz PJ, Pfeifer L, Bunse M, Uckert W, Holtappels R, Gillert-Marien D, Neuenhahn M, Krackhardt A, Reddehase MJ, Riddell SR, Busch DH.

Sci Transl Med. 2013 Jul 3;5(192):192ra87. doi: 10.1126/scitranslmed.3005958.

43.

CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia.

Green ML, Leisenring WM, Xie H, Walter RB, Mielcarek M, Sandmaier BM, Riddell SR, Boeckh M.

Blood. 2013 Aug 15;122(7):1316-24. doi: 10.1182/blood-2013-02-487074. Epub 2013 Jun 6.

44.

HLA engineering of human pluripotent stem cells.

Riolobos L, Hirata RK, Turtle CJ, Wang PR, Gornalusse GG, Zavajlevski M, Riddell SR, Russell DW.

Mol Ther. 2013 Jun;21(6):1232-41. doi: 10.1038/mt.2013.59. Epub 2013 Apr 30.

45.

Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells.

Hudecek M, Lupo-Stanghellini MT, Kosasih PL, Sommermeyer D, Jensen MC, Rader C, Riddell SR.

Clin Cancer Res. 2013 Jun 15;19(12):3153-64. doi: 10.1158/1078-0432.CCR-13-0330. Epub 2013 Apr 25.

46.

Proliferation-linked apoptosis of adoptively transferred T cells after IL-15 administration in macaques.

Berger C, Berger M, Beard BC, Kiem HP, Gooley TA, Riddell SR.

PLoS One. 2013;8(2):e56268. doi: 10.1371/journal.pone.0056268. Epub 2013 Feb 13.

47.

Cytomegalovirus-specific T cells are primed early after cord blood transplant but fail to control virus in vivo.

McGoldrick SM, Bleakley ME, Guerrero A, Turtle CJ, Yamamoto TN, Pereira SE, Delaney CS, Riddell SR.

Blood. 2013 Apr 4;121(14):2796-803. doi: 10.1182/blood-2012-09-453720. Epub 2013 Feb 14.

48.

Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale.

Wang X, Naranjo A, Brown CE, Bautista C, Wong CW, Chang WC, Aguilar B, Ostberg JR, Riddell SR, Forman SJ, Jensen MC.

J Immunother. 2012 Nov-Dec;35(9):689-701. doi: 10.1097/CJI.0b013e318270dec7.

49.

Chimeric antigen receptor--modified T cells: clinical translation in stem cell transplantation and beyond.

Riddell SR, Jensen MC, June CH.

Biol Blood Marrow Transplant. 2013 Jan;19(1 Suppl):S2-5. doi: 10.1016/j.bbmt.2012.10.021. Epub 2012 Oct 17. Review. No abstract available.

50.

Supplemental Content

Loading ...
Support Center